Pemphigus foliaceus (PF) is
Introduction
Autoimmune diseases are multifactorial disorders which involve both environmental and genetic factors. 1 There is convincing evidence that genetic susceptibility is complex, mediated by several predisposing polymorphic genes, no one being sufficient or required for the disease to occur 2 and that epistasis, ie the interaction between several loci, may enhance disease susceptibility. For example, major histocompatibility complex (MHC) class I and class II genes are classical loci associated with autoimmune disorders but many other genes encoding proteins shown to participate in the immunological processes have been found to be polymorphic and sometimes involved in the expression of the autoimmune trait. Among these, genes encoding autoantigens can contribute to disease susceptibility, as demonstrated by the association of the acetylcholine receptor alpha-subunit gene (CHRNA) polymorphism with myasthenia gravis. 3 Furthermore, in this organ-specific autoimmune disease, a three-gene model involving HLA class II DQA*0101, DRB*03 genes and CHRNA has been proposed that supports the concept of epistasis. 4 Pemphigus is a group of rare and severe cutaneous organ-specific autoimmune diseases, characterized by the production of autoantibodies directed against desmosomal adhesion molecules expressed by keratinocytes 5 and responsible for the formation of intraepidermal blisters. In the sporadic form of pemphigus foliaceus (PF) and fogo selvagem, its endemic form observed in certain areas of Brazil, pathogenic autoantibodies bind to desmoglein 1 (DSG1), [6] [7] [8] [9] [10] [11] [12] a glycoprotein that mediates cell adhesion in the superficial layers of the epidermis. MHC class II loci have been demonstrated to participate in susceptibility to both forms of PF. Fogo selvagem has been shown to be associated with HLA DRB1*0102, DRB1*0404, DRB1*1402 and DRB1*1406 alleles; 13, 14 and the sporadic form of PF with the FS-associated alleles DRB1*0102 and DRB1*0404 15 or with alleles previously found to be associated with pemphigus vulgaris, the other main subtype of pemphigus (DRB1*0402 and DRB1*1401 in Italy, 16 DRB1*0406 and DRB1*1401 in Japan 17 ). Recent experiments suggest that other genes may participate in PF susceptibility. Indeed, we recently reported a coding synonymous T/C single nucleotide polymorphism (SNP) at position 809 of the DSG1 gene which is associated with the sporadic form of PF in French patients. 18 Herewith, we determined HLA class II genotype in our series of 31 French Caucasian patients with PF that were previously selected to study DSG1 polymorphism 18 and asked whether DSG1 and HLA class II genes interact to confer higher susceptibility to PF.
Results

PF is associated with certain HLA class II genes
Low-resolution HLA-typing was performed in 31 French Caucasian PF patients (Table 1) and results were compared with those obtained from 84 healthy Caucasian volunteers randomly selected among the panel of the French National Histocompatibility Center. DRB1*04 and DRB1*14 were shown to be significantly associated with PF (Table 2 ), as already observed by others. Three-quarters of PF patients carried at least one of these alleles vs one-third of controls. High-resolution HLA typing confirmed that the PF association with DRB1*04 involved the two previously reported alleles, DRB1*0402 and DRB1* 0406 ( Table 2 ). Among DRB1*14 alleles, DRB1*1404 was the only subtype significantly associated with PF. The frequency of DRB1*0102 was also significantly higher in patients.
Because of the strong linkage disequilibrium between DR and DQ loci, all patients carrying DRB1*14 alleles also carried the DQB1*0503 allele, thereby suggesting PF association with the DRB1*1404-DQB1*0503 haplotype (Table 3 ). In contrast, despite the strong linkage disequilibrium between DRB1*04 and DQB1*0302, two DRB1* 0406-bearing patients did not have the DQB1*0302 allele. Therefore, although DQB1*0302 was significantly associa- ted with PF, it is likely that susceptibility is mediated by DRB1*04 alleles.
PF is associated with the SNP C/C(809) genotype
We recently identified a polymorphic marker of DSG1 that consisted of a single silent T to C transition at position 809 18 and polymerase chain reaction (PCR)-FauI digestion analysis showed that the allelic distribution of the C(809) differed significantly between PF patients and controls. This difference was confirmed in the current series involving the same PF patients (allelic frequency 40/62 = 64.5%) and a different control population made of 84 healthy Caucasian controls used in the present HLA association study (80/168 = 47.6%) (P = 0.03). The distribution of SNP(809) genotypes also differed between patients and controls (P = 0.05, 2 , 2 df) since the percentage bearing the C/C(809) genotype was higher for patients (13/31 = 41.9%) than controls (17/84 = 20.2%) (odds ratio: 2.86, 95% CI: 1.1-8.1, P = 0.03) (Figure 1 ).
C/C(809) genotype and DRB1*04 interact to enhance PF susceptibility in Caucasians
The demonstration that both HLA class II and DSG1 loci are involved in PF invited us to examine whether the genetic markers of the disease were independently distributed or combined significantly in PF patients. Examination of the relative distribution of DR4 and SNP(809) genotypes provided evidence for a preferential association of DR4 and C/C(809) genotype in patients but not in controls (Table 4) . Indeed, in patients carrying the 207 C/C(809) genotype, 84.6% (11/13) also had the DRB1*04 allele vs 33.3% (6/18) in C/C(809)-negative PF patients (P = 0.004, Figure 2c and a). In contrast, DRB1*04 representation was stable in controls, regardless of the C/C(809) genotype: 35.3% (6/17) vs 29.9% (20/67) (P = 0.76, Figure 2d and b) . This prompted us to compare the effect of the DR4 haplotype on disease susceptibility respectively in C/C(809) + and C/C(809) − subjects which brought evidence for a significant combination of both risk factors in patients. Indeed, when the C/C(809) genotype was present, the percentage of DRB1*04 carriers was signifi- cantly higher in PF patients (11/13 = 84.6%) than controls (6/17 = 35.3%) (P = 0.02, OR = 10.08, 95% CI: 1.36-113.2, Figure 2c and d). In contrast, when the C/C (809) genotype was absent, the percentages of DRB1*04 carriers among PF patients (6/18 = 33.3%) and controls (20/67 = 29.9%) were similar (P = 0.77, OR = 1.175, 95% CI: 0.32-3.98, Figure 2a and b). Heterogeneity in the relative distribution of DR4 and C/C(809) in patients vs controls was confirmed by the Mantel-Haenszel test (P = 0.04) which demonstrates preferential combination of DR4 and C/C(809) genotype in patients and therefore epistatic interaction between the two polymorphic markers. Comparison of odds ratio (OR) using Paul and Doner method confirmed that the joint presence of DRB1*04 and C/C(809) genotype represented a significantly higher risk for PF (OR = 10.08) than either alone ( 2 = 5.629 ddl = 1, P = 0.02). Finally, epistasis between the two genes was confirmed by logistic regression analysis in which PF was considered as a dependent variable, and DRB1*04 (absence or presence) and SNP C/C(809) genotypes (presence or absence) were included in the model as independent variables: only the interaction term HLA-SNP(809) was significant in the model (P = 0.05, OR = 8.6, 95% CI: 1.03-71.41). Therefore, these different statistical models converge to show that the effect of both risk factors is more than additive and to demonstrate an epistasis between DR4 and C/C genotype in PF susceptibility.
Discussion
Genetic factors play critical roles in the development of autoimmunity. Recent data obtained from the analysis of organ-and non-organ-specific autoimmune diseases, in particular, insulin-dependent diabetes mellitus (IDDM) 2 and systemic lupus erythematosus (SLE), 19 indicate that multiple loci acting independently or not constitute the genetic basis for susceptibility to autoimmune disorders. For example, in human SLE, linkage analysis of sib-pairs and extended family pedigrees detected linkage with nine genomic intervals, 20 of these, two interact to mediate the autoimmune process. 21 This phenomenon of epistasis provides a working model to analyze the genetic predisposition to other autoimmune diseases and may very well constitute a more general genetic mechanism.
Herewith, we report results indicating that two different loci interact to participate in the development of PF, a rare but informative model of organ-specific autoimmune disease. The two loci studied were MHC class II genes and DSG1 which encodes the target autoantigen of the pathogenic antibodies produced during the course of PF. The rationale to study the role and the interaction of these two genetic elements was: first, MHC class II genes have been shown to play a pivotal role in most autoimmune diseases and also to be associated with the endemic 13, 14 and the sporadic forms [15] [16] [17] of PF; and, second, it is well established that autoantigens participate in the triggering of the B-and T-cell autoimmune responses in autoimmune diseases, and that polymorphism of the corresponding autoantigen can contribute to the autoimmune trait susceptibility as shown for the CHRNA gene in myasthenia gravis 3 and the insulin gene in IDDM. 22 In this association analysis involving the largest series of PF patients so far studied and 84 healthy controls, HLA-DRB1*0102, DRB1*0402 and 0406 and DRB1*1404 were shown to be significantly associated with PF. These data are consistent with results from three recent studies showing the association of the sporadic form of PF with DRB1*0102 and DRB*0404 in French Caucasians, 15 with DRB1*0402 and DRB1*1401 in Italian Caucasians 16 and with DRB1*0406 and DRB1*1401 in Japanese. 17 One should also note that our study points to an association of PF with DRB1*0402 and with DRB1*1404 that were previously demonstrated to be associated with pemphigus vulgaris (PV), a subtype of pemphigus in which autoantibodies are directed against DSG3, another keratinocyte adhesion molecule of the cadherin family. This observation previously made by Lombardi et al 16 in Italian Caucasians suggests that these HLA-class II alleles contribute to both PF and PV. This point is consistent with the presence, in more than 50% of PV patients, of both anti-DSG1 and anti-DSG3 antibodies 8 and T cells. 23 This may indicate that susceptibility class II molecules which are shared by PV and PF are able to present peptides from both DSG1 and DSG3, whereas, class II molecules which are specific of either PV or PF can specifically present peptides from respectively DSG3 and DSG1. The homozygous C/C(809) genotype at the DSG1 gene was also shown to be significantly associated with PF. Whether the C/C(809) genotype contributes specifically to PF or more generally to the production of anti-DSG1 antibodies in both PF and PV could be addressed by studying DSG1 polymorphism in PV patients producing anti-DSG1 antibodies. This study is underway in our laboratory. Furthermore, the combination of HLA-DR4 and C/C(809) genotype conferred a stronger risk of PF development as demonstrated by the analysis of the effect on the distribution of the DR4 haplotype in PF patients stratified according to the SNP(809) genotype. No conclusion could be drawn from the association between the DR4 subtypes and the C/C(809) genotype, as subgroups were to small for statistical significance. However, one can notice that all but one PF patients (5/6) bearing the disease-associated DR4 subtypes ie, DRB1*0402 and DRB1*0406, also have the C/C(809) genotype. This observation of epistatic interaction is reminiscent of results obtained in two other organ-specific autoimmune diseases, in which the interactive effect of two different loci was demonstrated: IDDM with the insulin gene and the HLA region, 24 and myasthenia gravis with CHRNA and two different HLA loci. 3, 4 How HLA class II genes and the C/C(809) genotype interact to mediate PF susceptibility might be explained by the fact that MHC class II molecules and autoantigens intervene in the biological pathway leading to the autoimmune processes and tolerance breakage of autoreactive lymphocytes, since MHC gene products present antigens to immune T cells. 25 The C/T polymorphism at position 809 is a silent mutation and therefore, does not directly modify a putative T-cell epitope on the corresponding region of DSG1. However, preliminary results showing an alternative splicing of the 3Ј extremity of the intron 6 of the DSG1 gene, located 50-bp upstream to the SNP(809), allow to consider the role of the SNP(809) on the regulation of this alternative splicing. The hypothesis of a new isoform of DSG1, resulting from this alternative splicing and involved in tolerance breakage, is currently under investigation and should provide functional basis for the present genetic association.
In any case, this study emphasizes the complexity of genetic interactions in the development of autoimmune diseases and the role of epistasis between genes encoding presentation molecules and autoantigen in PF susceptibility.
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Subjects and methods
Patients and controls
Thirty-one Caucasian PF patients recruited from French Dermatology Departments were enrolled in the study (Table 1) . They all fulfilled clinical, histological and immunohistochemical criteria for PF diagnosis. Briefly, histological examination of skin lesions showed superficial acantholysis and/or eosinophilic spongiosis and typical intercellular deposition of IgG and/or C3 was observed in perilesioned skin of all patients. Anti-DSG1 (160 kDa) antibodies were detected by immunoblot using human skin extract as the antigen 26 in 15 patients (48.4%), a frequency similar to that usually reported. 27 Eighty-four healthy Caucasian volunteers were randomly selected among the representative panel of the French National Histocompatibility Center (Hopital Saint-Louis, Paris, France) to constitute the control population.
HLA molecular typing
Genomic DNA was extracted from peripheral blood leukocytes and used for DRB1 and DQB1 typing. PCR sequence-specific oligonucleotides (PCR-SSO) reverse dot-blot kits (InnoLipa DRB key and InnoLipa DQB kits, Innogenetics, Zwijndrecht, Belgium) were used for medium-resolution typing and completed with a PCR sequence-specific primer (PCR-SSP) and PCR restriction fragment length polymorphism (PCR-RFLP) technique for DRB1*01, DRB1*04 and DRB1*14 allelic determination. 28 HLA DRB1 was genotyped for 31 patients and 84 controls, and HLA DQB1 for 30 patients and 64 controls.
Detection of SNP(809) in DSG1
We previously reported a coding synonymous SNP at position 809 of DSG1 since the T(809) of the initially published sequence is substituted by a C(809) in 48.5% of the alleles in a healthy French population. 18 The silent T to C transition creates a restriction site that can be detected by PCR-FauI digestion assay. Briefly, PCR products amplified from genomic DNA were digested by FauI (Sibenzyme, Novosibirsk, Russia) and run through a 3% Agarose gel that discriminated undigested (225 bp) from digested (150 bp + 75 bp) products and identified SNP(809) genotypes (C/C: complete digestion, T/C: incomplete digestion, T/T: no digestion).
Statistical analysis
Phenotypic and allelic frequencies were compared between patients and controls using the 2 test with Yates' correction or Fisher's exact test when necessary. The corrected P value (Pc) was obtained by multiplying the P value by the number of tested alleles at each locus. When an association already observed by others was found, the P value was not corrected. To evaluate the respective contribution of HLA and DSG1 loci to disease susceptibility, different statistical methods were used. The methods of Mantel-Haenszel, 29 Paul and Donner 30 and Gart 31 enabled us to compare odds ratios attributed to DRB1*04 according to the presence or absence of the C/C(809) genotype. These tests were completed by logistic regression including an interaction term between HLA and DSG1. HLASTAT software was used for comparison of frequencies and odds ratio calculation, and SPSS statistical software for logistic regression.
